Individual HCPs

Academic centre lead with a high HR+/HER2- caseload; data-driven and generally an early adopter where benefit is clear.

Weighs quality-of-life and tolerability heavily; supportive but wants durability data before changing practice.

Pragmatic prescriber focused on real-world applicability and access; cautious on cross-trial comparison.

Strong advocate for the mechanism; views the endpoint as clinically meaningful and readily adoptable.

Balances efficacy signals with patient selection; supportive in defined subgroups.

Conservative adopter; unconvinced by effect size relative to existing pathways and wary of toxicity trade-offs.

Supportive with conditions; emphasises multidisciplinary input and monitoring burden.

Focused on tolerability, dose management and adherence; measured on efficacy claims.

Early adopter where data are strong; interested in ctDNA-guided decisions and sequencing.

Mixed views; concerned that trial populations differ from the patients seen in routine practice.

Sees a clear unmet need; enthusiastic where benefit magnitude is convincing.

Sceptical of incremental benefit; prefers to wait for longer follow-up and mature data.

Confident in the data; ready to adopt and comfortable with the safety management required.

Neutral-to-mixed; highlights dose interruptions and practical management considerations.

Broadly supportive; values consistency with prior clinical experience of the class.

Conditionally positive; wants clarity on patient selection and comparative positioning.